31, the FDA granted Pre-market Approval (PMA) to Roche for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay, for use on the cobas e 601 analyzer.
What does HBc stand for?
HBc stands for Hepatitis B Core
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of HBc
We have 244 other meanings of HBc in our Acronym Attic
- Havant Borough Council (UK town council)
- Hawker Beechcraft Corporation (Wichita, Kansas)
- Head Ball Coach (Steve Spurrier)
- Health & Beauty Care
- Health Benefits Coalition (healthcare)
- Healthcare Business Consultants (various locations)
- Heavy Brushed Cotton (fabric)
- Helena Bonham Carter (actress)
- Hellenic Bottling Company (Coca-Cola)
- Helsinki Business College (Finland)
- Heritage Bible Church (various locations)
- Hertsmere Borough Council (UK)
- Heyington Bridge Crew (Richmond Eagles Football Club supporter group)
- High Breaking Capacity
- High Brutality Clan (gaming)
- High Butt Crack
- Hilltop Baptist Church (Colorado Springs, Colorado)
- Hilvarenbeekse Bridge Club
- Hispanic Broadcasting Corporation
- Hispanic Business Council
Samples in periodicals archive:
Laboratory analysis Serological testing included hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B surface antibody (anti-HBs) and hepatitis early (e) antigen HBeAg) and antibody (anti-HBe) using the Axsym assay with the MEIA methodology (Abbott Laboratories, Ill.
Except for 1 patient whose serum tested positive for antibodies to hepatitis B core antigen, no positive serologic results for other hepatitis viruses (including hepatitis A) were reported in the patients from Victoria.
It has been shown that Hepatitis B surface (HBsAg) and core antigen (HBcAg) induces envelope-and core specific CD4+ and CD8+ T-cell responses and that the response against the Hepatitis B core antigen (HBcAg), is often associated with viral control.
based immunotherapy company, today announced a joint collaboration in which the companies will continue the development of a therapeutic hepatitis B vaccine, containing Corixa's RC-529(TM) adjuvant and Lorantis' CV-1831, a hepatitis B core antigen that was previously owned by Apovia, Inc.
A proof of principle study, completed in the first half of this year, has shown that the use of hybrid hepatitis B cores expressing surface hepatitis B virus components do augment the immune response to hepatitis B in a pre-clinical setting.